These results, together with a preceding report demonstrating that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like behavior in mice,2 support the strategy of targeting ACKR3 as a singular strategy to modulate the opioid process, which could open up new therapeutic avenues for opioid-linked disorders.(2) The medical doctor has receive